Collectively, these findings have identified the β2-AR as a therapeutic target that can potentially be exploited to improve anti-tumor immunity, and to mobilize more effective lymphocytes to blood where they can be readily accessed for the ex vivo manufacture of more potent cell products for cancer therapy. This evidence concerns the gene ADRB2 and cancer.